TABLE 1.
Demographics of recipient cohort at the time of transplantation
| Baseline characteristics | Total population |
|---|---|
| (n = 5752) | |
| Age (y), mean (SD) | 53.8 ± 13.9 |
| Male, n (%) | 3514 (61.1) |
| Recipient BMI pretransplant (kg/m2), median [IQR] | 28.7 [24.7–33.3] |
| Race, n (%) | |
| White | 3807 (66.2) |
| Black race | 776 (13.5) |
| Hispanics | 546 (9.5) |
| Others | 623 (10.8) |
| Pretransplant cause of ESRD, n (%) | |
| Glomerulonephritis | 1522 (26.5) |
| Diabetes mellitus | 1376 (23.9) |
| Hypertensive nephrosclerosis | 701 (12.2) |
| Cystic diseases | 688 (12.0) |
| Retransplant | 594 (10.3) |
| Uropathy | 180 (3.1) |
| Unknown/others | 691 (12.0) |
| Dialysis pretransplant, n (%) | 4012 (69.8) |
| Prior kidney transplant, n (%) | 594 (10.3) |
| cPRA ≥ 80% (n = 4941)a | 528 (10.7%) |
| Living donor transplant, n (%) | 2827 (49.2) |
| Donor age (y), n (%) | 42.2 ± 14.6 |
| Donor male, n (%) | 2904 (50.5) |
| Induction, n (%) | |
| Alemtuzumab | 2449 (42.6) |
| Thymoglobulin | 1932 (33.6) |
| Anti-CD25 | 1367 (23.8) |
| None | 4 (0.07) |
| Maintenance immunosuppression, n (%)b | |
| Tacrolimus, MMF, and prednisone | 3064 (53.3) |
| Tacrolimus, MMF | 2600 (45.2) |
| Others | 88 (1.5) |
| Maintenance prednisonec | 3120 (54.2%) |
| DGFd | 1267 (22.0%) |
acPRA was calculated using data from UNOS STAR information available in 4941 patients.
bMaintenance immunosuppressant used in the first 4 mo or last censored day prior the first 4 mo.
cChronic maintenance of prednisone as an immunosuppressant after induction.
dDelayed graft functioning defined as requiring dialysis the first week posttransplant.
BMI, body mass index; cPRA, calculated panel reactive antibody; DGF, delayed graft functioning; ESRD, end-stage renal disease; IQR, interquartile range; MMF, mycophenolate mofetil.